Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Management of Recurrent Coarctation in ChildrenCoarctation of the aorta accounts for 5-8% of all congenital heart disease, with an incidence of approximately four cases per 10,000 live births. It can be seen in isolation or associated with other cardiac lesions.
- Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 MonoagonistsAmycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, according to two studies published in The Lancet.
- CAPLA: Long-Term QOL Improvement With CA For Persistent AFibQuality of life (QOL) at three years significantly improved following catheter ablation (CA) for persistent atrial fibrillation (PsAFib), according to a secondary analysis of patients in the CAPLA clinical trial published in JACC: Clinical Electrophysiology.
- Thrombotic Events In ATTR-CM Patients Linked to Primary LA CardiopathyPrimary left atrial (LA) cardiopathy appears to be linked to the high risk of thrombotic events (TE) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) independent of atrial fibrillation (AFib), CHA2DS2-VASc score and LA dilatation. This link differs from patients with other left ventricular hypertrophy (LVH) phenotypes according to a new study published in JACC: Cardiovascular […]
- REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or PlaceboThe combination of cagrilintide with semaglutide (CagriSema) in a single weekly injection was associated with a significantly greater weight loss in adults with overweight or obesity regardless of type 2 diabetes (T2D) status compared with placebo or either drug alone...